证券记录 · 已归档季度
PTGX
Protagonist Therapeutics, Inc. · Healthcare · Biotechnology
17被追踪持有人
0Δ持有人
26.31M持有股份
$1.75B报告持仓市值
+2新建仓位
−2清仓
动量输入（同类管理人）： 持有人广度 0.0% · 股份流向 +7.0% · 净新建仓位 0.0% · 公式
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | +1 | 115.23K | $16.23M | +1 | n/a |
| Q2 2026 | 106 | +1 | 45.41M | $5.57B | +7 | −6 |
| Q1 2026 | 108 | -1 | 49.99M | $5.27B | +9 | −10 |
| Q4 2025 | 107 | +4 | 45.87M | $4.01B | +4 | n/a |
| Q3 2025 | 17 | 0 | 26.31M | $1.75B | +2 | −2 |
| Q2 2025 | 14 | -1 | 22.53M | $1.25B | +1 | −2 |
| Q1 2025 | 12 | +1 | 7.51M | $363.26M | +3 | −2 |
| Q4 2024 | 11 | -2 | 7.82M | $302.00M | n/a | −2 |
| Q3 2024 | 12 | +2 | 4.92M | $221.52M | +3 | −1 |
| Q2 2024 | 10 | n/a | 7.44M | $257.83M | n/a | n/a |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (被动) | 9.40M | -2.4% | $624.72M | 0.0% | ▼ Trim | 2 | SEC ↗ ×18 |
| 2 | The Vanguard Group ✦ (被动) | 4.26M | -2.3% | $282.81M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (被动) | 3.17M | -1.3% | $210.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Wellington Management ✦ | 1.91M | +83.9% | $126.78M | 0.0% | ▲ Add | 5 | SEC ↗ ×7 |
| 5 | Geode Capital Management ✦ (被动) | 1.42M | -1.9% | $94.12M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 6 | T. Rowe Price ✦ | 1.22M | +30.3% | $81.08M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Marshall Wace ✦ | 1.09M | 新增 | $72.11M | 0.1% | New | 1 | SEC ↗ ×2 |
| 8 | Goldman Sachs Group ✦ | 781.71K | n/a | $51.93M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 9 | Morgan Stanley ✦ | 768.36K | n/a | $51.04M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 10 | Adage Capital Partners ✦ | 718.20K | -34.2% | $47.71M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 11 | Fidelity (FMR) ✦ | 520.66K | -3.3% | $34.59M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 12 | JPMorgan Chase ✦ | 504.80K | n/a | $33.53M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 13 | Citadel Advisors ✦ | 237.88K | +774.5% | $15.80M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 14 | Duquesne Family Office ✦ | 159.70K | 新增 | $10.61M | 0.3% | New | 1 | SEC ↗ |
| 15 | Millennium Management ✦ | 127.56K | +739.7% | $8.47M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 22.20K | -40.5% | $1.47M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 8.57K | -50.8% | $569,305 | 0.0% | ▼ Trim | 6 | SEC ↗ ×4 |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Marshall Wace | $72.11M | 0.1% |
| Duquesne Family Office | $10.61M | 0.3% |
已清仓
| Renaissance Technologies | $9.57M | 曾为 0.0% |
| Arrowstreet Capital | $986,901 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 310 持有人, 71.79M 股份, $7.31B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Sep 30
Ali Asif
Officer · 46.03K 股 · $6.53M
Sep 30
Ali Asif
Officer · 12.60K 股 · $1.79M
Sep 10
PATEL DINESH V PH D
Officer, Director · 7.28K 股 · $1.05M
Sep 09
PATEL DINESH V PH D
Officer, Director · 63.55K 股 · $9.29M
Sep 08
PATEL DINESH V PH D
Officer, Director · 54.17K 股 · $7.90M
Aug 11
PATEL DINESH V PH D
Officer, Director · 34.24K 股 · $5.09M
Aug 10
PATEL DINESH V PH D
Officer, Director · 65.76K 股 · $9.81M
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Aug 13
SC 13G/A: FARALLON CAPITAL MANAGEMENT, L.L.C.
Aug 07
SC 13G: STATE STREET CORP
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据